The Internet is a double-edged sword, presenting at once possibilities for business opportunities undreamed of twenty years ago – fast and cheap communications, multitudes of customers, “frictionless” commerce – and possibilities for fraudulent practices on a scale heretofore unimagined – Ponzi, pyramid, and illegal “multi-level marketing” (MLM) schemes that can use the reach of the Internet to victimize tens of thousands of people. Where do cryptocurrencies like Bitcoin (the most popular and well known), Ethereum, and Ripple and efforts to market them fit into this mix of legitimate and fraudulent activities?
His practice includes the representation of drug manufacturers and other commercial entities in industry-wide multi-plaintiff and class action litigation involving alleged price-fixing and other collusive conduct, claims of fraud, violations of RICO, Walker Process patent-based antitrust claims, and in enforcement actions against the sale of illegally imported and diverted drugs and medical devices. Rob also represents drug industry clients in connection with Federal Trade Commission investigations and enforcement actions, and served as co-lead counsel to a major international drug manufacturer in the defense of nationwide litigation challenging industry pricing practices. Rob is also outside counsel to and Corporate Secretary of, the Pharmaceutical Security Institute, Inc., the brand name pharmaceutical industry’s not-for-profit trade organization dedicated to the fight against pharmaceutical counterfeiting.
Outside the pharmaceutical industry, Rob's principal work has been in defending against RICO, False Claims Act, antitrust, and other claims based on federal statutes. Much of this work has involved U.S. litigation against foreign businesses. He is Managing Editor of The World in US Courts: Orrick's Quarterly Review of Decisions Applying US Law to Global Business and Cross-Border Activities.
Rob also has extensive experience representing clients in product safety matters before the U.S. Consumer Product Safety Commission.
Prior to joining Orrick, Rob was a partner in Hughes Hubbard & Reed LLP, where he served as co-chair of the firm’s Pharmaceutical and Healthcare Industry and Product Safety Practice Groups. He was also the Washington, D.C., Office Pro Bono Coordinator.
Posts by: Robert Reznick
The question whether and under what circumstances the Lanham Act and the Copyright Act will be applied to conduct occurring at least partially outside the United States grows increasingly important as the world economy continues to globalize and many manufacturers seek to extend their franchises across borders. Two recent federal court decisions have addressed this issue, underscoring the somewhat anomalous differences in extraterritorial enforcement of trade dress and copyright laws, as well as the ability of plaintiffs to obtain injunctive relief with extraterritorial effect. READ MORE